Back

Does chlorotoxin target matrix metalloproteinase-2 in glioblastoma?

Blaney, E.; Demeke, M.; Kamayirese, S.; Monga, L.; Hansen, L. A.; Watts, C. R.; Lovas, S.

2025-07-16 biophysics
10.1101/2025.07.11.664294 bioRxiv
Show abstract

Glioblastoma aggressively invades surrounding tissue by expressing matrix metalloproteinase-2 (MMP-2). Therefore, effective inhibition of MMP-2 is a desirable target for treatment. In some reports, the chlorotoxin (Ctx) polypeptide produced by the scorpion Leiurus quinquestriatus, interacts with human MMP-2 to inhibit tumor invasion without affecting surrounding tissue. We employed three molecular docking methodologies followed by molecular dynamics simulations to find consensus binding and calculate the binding energy of these peptide ligands to MMP-2. In addition to the Ctx itself, four C-terminal fragments were chosen to study their binding to MMP-2. The molecular docking platforms HPEPDOCK, HADDOCK, and AlphaFold2 created peptide - protein poses for each candidate binding to MMP-2. These poses underwent 500 ns molecular dynamics simulations. Peptide binding on MMP-2 and final binding energies were calculated using the Molecular Mechanics Poisson-Boltzmann Surface Area method. Configurational entropy and root-mean square deviation analyses showed stable peptide - protein complexes. Ctx and its peptide fragments frequently bound to regions on MMP-2 other than the catalytic site. All docking methods shared consensus on large negative binding energies, indicating favorable interaction between Ctx and its analogs with MMP-2. While Ctx and its fragments bind to MMP-2, there is no consensus on which region of MMP-2 they are bound to or which peptide binds strongest. Neither Ctx nor its fragments inhibited MMP-2 enzymatic activity, however, glioblastoma cellular migration was inhibited. Interactions with the non-catalytic regions of MMP-2 suggest allosteric binding to MMP-2. Inhibition of cellular migration without inhibition of MMP-2 activity warrants further study into the possible targets of Ctx expressed in glioblastoma.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 12%
15.0%
2
Scientific Reports
3102 papers in training set
Top 8%
8.8%
3
Biochemistry and Biophysics Reports
28 papers in training set
Top 0.1%
6.7%
4
Frontiers in Molecular Biosciences
100 papers in training set
Top 0.1%
5.1%
5
Journal of Biomolecular Structure and Dynamics
43 papers in training set
Top 0.2%
5.1%
6
Archives of Clinical and Biomedical Research
28 papers in training set
Top 0.1%
5.1%
7
Bioscience Reports
25 papers in training set
Top 0.1%
4.5%
50% of probability mass above
8
International Journal of Molecular Sciences
453 papers in training set
Top 2%
4.1%
9
Biomolecules
95 papers in training set
Top 0.1%
4.1%
10
Life
27 papers in training set
Top 0.1%
2.9%
11
ACS Chemical Neuroscience
60 papers in training set
Top 0.7%
2.7%
12
Biomedicines
66 papers in training set
Top 0.6%
1.9%
13
Molecular Pharmaceutics
16 papers in training set
Top 0.2%
1.9%
14
International Journal of Biological Macromolecules
65 papers in training set
Top 1%
1.8%
15
PeerJ
261 papers in training set
Top 6%
1.8%
16
ACS Omega
90 papers in training set
Top 2%
1.6%
17
Neuroscience Letters
28 papers in training set
Top 0.5%
1.6%
18
Cells
232 papers in training set
Top 4%
1.3%
19
Molecules
37 papers in training set
Top 1%
0.9%
20
Frontiers in Pharmacology
100 papers in training set
Top 4%
0.8%
21
Toxins
14 papers in training set
Top 0.1%
0.8%
22
Biochimie
23 papers in training set
Top 0.4%
0.8%
23
Biophysical Chemistry
14 papers in training set
Top 0.2%
0.7%
24
FEBS Open Bio
29 papers in training set
Top 0.7%
0.7%
25
Cancers
200 papers in training set
Top 5%
0.7%
26
BioMed Research International
25 papers in training set
Top 4%
0.7%
27
iScience
1063 papers in training set
Top 39%
0.5%
28
Frontiers in Microbiology
375 papers in training set
Top 10%
0.5%
29
Molecular Therapy Nucleic Acids
32 papers in training set
Top 1%
0.5%